Company Overview of Liquidia Technologies, Inc.
Liquidia Technologies, Inc., a nanotechnology company, designs, develops, and manufactures precisely engineered particles and films for applications in life and materials science sectors. It develops micro and nanoparticles for the delivery of biological and small molecule therapeutics, as well as for the development of vaccines and inhaled therapeutics in the life sciences sector. The company also develops nano-patterned optical films for displays, lighting, photovoltaics, and related applications in the material science sector. Liquidia Technologies, Inc. was founded in 2004 and is based in Research Triangle Park, North Carolina.
419 Davis Drive
Morrisville, NC 27560
Founded in 2004
Key Executives for Liquidia Technologies, Inc.
Chief Executive Officer and Director
Co-Founder and Senior Scientist
Compensation as of Fiscal Year 2014.
Liquidia Technologies, Inc. Key Developments
Liquidia Announces Formation of Lq3 Pharmaceuticals
Sep 10 14
Liquidia Technologies announced the formation of a new pharmaceutical company, Lq3 Pharmaceuticals, dedicated to advancing novel therapies for oral health conditions. Leveraging the PRINT(R) (Particle Replication In Non-Wetting Templates) technology, Lq3 will initially focus on research and preclinical development of a lead, but currently undisclosed oral health product candidate. Like Envisia Therapeutics, Lq3 will leverage the transformative PRINT technology, a micro- and nanoparticle development and manufacturing platform known for its unique ability to control particle size, shape and chemistry. The PRINT technology provides a basis for the creation of innovative products that have the potential to address significant unmet needs in a wide range of medical conditions.
Liquidia Technologies Appoints Timothy Albury as Chief Financial Officer
Jun 25 13
Liquidia Technologies announced that Timothy Albury has been named the company's Chief Financial Officer (CFO). In this role, Mr. Albury will be a key member of the executive management team that is responsible for leading the overall strategy and direction of the company, while also maintaining fiscal oversight of the company's management and operations, including facilities and IT. Mr. Albury joins Liquidia from Osmotica Pharmaceutical Corp.
Liquidia Technologies Announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine
May 21 13
Liquidia Technologies announced that its collaborative agreement with PATH has been extended. The extension of this agreement allows for the continuation of preclinical proof-of-concept studies on a next generation pneumococcal vaccine. If successful, the vaccine could potentially allow for broadened efficacy and manufacturing efficiencies that translate to greater access to the vaccine by the global population. Pneumonia kills approximately 1.3 million children under the age of five years every year more than any other illness. Nearly half of these deaths are caused by Streptococcus pneumoniae, a bacterium that has many variations globally and is becoming increasingly resistant to antibiotics. The complexity and inefficiency of this approach limits strain coverage and global availability. Because of the unique features of the PRINT(R) (Particle Replication In Non-Wetting Templates) platform, Liquidia has the ability to use particle-based design strategies to bring together the polysaccharide and carrier protein without traditional conjugation, opening up novel product opportunities for a variety of bacterial diseases, including Streptococcus pneumoniae.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|